Unique responses of limbic met-enkephalin systems to low and high doses of methamphetamine.
A single administration of a low (0.5 mg/kg) or high (10 mg/kg) dose of methamphetamine (METH) significantly altered the met-enkephalin (M-Enk) systems associated with some, but not all, limbic structures examined. Neither treatment influenced M-Enk levels 3 h after drug exposure in any limbic region studied; however, 12 h after drug administration, 0.5 mg/kg of METH reduced the tissue content of this peptide in both the nucleus accumbens shell (NAs) and the frontal cortex (FrCx). This was similar to the effect of this treatment on the anterior striatal region. In contrast, the high dose of METH increased M-Enk content in the frontal cortex and anterior striatum (AS), but had no effect in the nucleus accumbens shell. By 24 h, the effects of METH in the anterior striatum subsided, but decreases in M-Enk levels were still observed after both the low- and the high-dose METH treatments in the nucleus accumbens shell. The levels of M-Enk were not changed at any of the time points examined in the core of the nucleus accumbens (NAc). In general, treatment with a low or high dose of METH causes distinct and regional selective changes in the tissue levels of M-Enk in the limbic system. These changes appear to be mediated by dopamine (DA) D(2) and D(1) receptor activation.
Alburges
M E
ME
Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, 30 So. 2000 E., Room 201, Salt Lake City, UT 84112-5820, USA. m.e.alburges@m.cc.utah.edu
Keefe
K A
KA
Hanson
G R
GR
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology*; D000818:Animals; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004744:Enkephalin, Methionine / Q000378:metabolism*; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism; D007150:Immunohistochemistry; D008032:Limbic System / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D009434:Neural Pathways / Q000187:drug effects* / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism
D018759:Adrenergic Uptake Inhibitors; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D008694:Methamphetamine; D004744:Enkephalin, Methionine; D004298:Dopamine